In order to further understand how glioma-derived IL-33 is orchestrating the changes within the TME and based on the significant increase of anti-inflammatory mediators (Fig. 5), including a number of signaling molecules observed in IL-33+ tumors, we performed phosphoproteomic analysis using mass spectrometry on the brains of tumor-bearing mice. The gene discussed is IL33; the disease is glioma.